DUPLIVIR® (tenofovir disoproxil fumarate + lamivudine)

  • ACTIVE INGREDIENT: tenofovir disoproxil fumarate + lamivudine
  • CONCENTRATION: 300mg per each
  • PRESENTATION: 30 coated tablets


DUPLIVIR® belongs to a group of antiviral drugs, also known as antiretrovirals, and is indicated for the treatment of HIV-1 infection.


DUPLIVIR® is contraindicated in patients with previously demonstrated hypersensitivity to any of the product’s components.

As this is a tablet containing the combination of lamivudine and tenofovir disoproxil fumarate, DUPLIVIR® should not be co-administered with other drugs containing lamivudine or tenofovir disoproxil fumarate. Due to the similarities between emtricitabine and lamivudine, DUPLIVIR® should also not be co-administered with products containing emtricitabine. There is interaction between zalcitabine and laminudin, therefore coadministration of zalcitabine and DUPLIVIR® is not recommended.

DUPLIVIR® should not be coadministered concomitantly with drugs based on adenofovir dipivoxil.

It is not recommended to use DUPLIVIR® as a component of a three-nucleoside administration program.

Patients with renal insufficiency should not use DUPLIVIR®, because dose adjustment is not possible.

There are no age-related contraindications; however, safety and efficacy in pediatric patients under 18 years of age have not been established.


Rua Doutor Mario Augusto Pereira, 100, Galpão B, Jardim São Paulo, Taboão da Serra, São Paulo, CEP: 06767-330 • © Blanver 2020, Todos os direitos reservados